The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Share News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sensyne reports "disappointing" first half, with revenue decline

Mon, 31st Jan 2022 11:13

(Alliance News) - Sensyne Health PLC said on Monday that revenue fell year-on-year in the first half of its financial year, as losses widened following a "challenging" period for the clinical artificial intelligence company.

The Oxford, England-based firm reported a pretax loss of GBP21.1 million for the six months ended October 31, widening from GBP13.8 million in the same period a year prior.

Revenue had more than halved for the period, down 57% year-on-year to GBP1.0 million, from GBP2.3 million. Revenue came mostly from a contract for AI medical imaging app MagnifEye with the Department for Health & Social Care, a life science agreement with Bristol Myers Squibb, and uptake of sales in GDm-Health, a remote monitoring app for gestational diabetes patients.

"Whilst our commercial progress in the year to date has been disappointing, we remain confident about the company's long-term prospects, given the size of our database, the strength of our medical and data science expertise, the growth of our business development pipeline, and the significant interest Sensight is now generating from potential customers," said Chief Executive Officer Paul Drayson.

Operating expenses were up 44% in the period, as the company increased its headcount for research and development in its Sensight data analytics platform. Gross margin relative to revenue fell during the period to 44% from 58%, owing to a change in sales mix of agreements with life science clients.

Cash on October 31 was GBP8.1 million, down from GBP18.6 million on October 31, 2020.

The company announced it had secured of GBP11.4 million in much-needed financing for its short term needs on Wednesday. However, it said customers may have to wait until its long-term financial position is clarified before confirming orders. It believes up to GBP26 million of contracts could be brought in during the financial year, but this could be "very materially lower" if its long-term financial outlook remains precarious.

Sensyne's share price fell 5.9% to 19.30 pence each in London on Monday morning. It has fallen 76% in value since the start of 2022.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
7 May 2021 19:23

IN BRIEF: Sensyne Health gets UK heath regulator boost

IN BRIEF: Sensyne Health gets UK heath regulator boost

Read more
7 May 2021 08:55

Sensyne's 'MagnifEye' gets MHRA special use authorisation

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health announced on Friday that its 'MagnifEye' software application, which uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted special use authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA).

Read more
30 Apr 2021 14:45

Sensyne Health signs research deal with another NHS trust

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health has signed a five-year non-exclusive strategic research agreement (SRA) with the Royal Devon and Exeter NHS Foundation Trust, it announced on Friday.

Read more
30 Apr 2021 14:15

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

Read more
12 Mar 2021 13:03

IN BRIEF: Sensyne signs deal with UK government to fund Covid tests

IN BRIEF: Sensyne signs deal with UK government to fund Covid tests

Read more
12 Mar 2021 09:23

Sensyne signs £0.5m Covid-19 test deal with DHSC

(Sharecast News) - Clinical artificial intelligence (AI) technology company Sensyne Health has signed a £0.47m agreement with the Department of Health and Social Care, it announced on Friday, to conduct the second stage of a pilot study of its 'MagnifEye' technology for use with Covid-19 lateral flow diagnostic tests.

Read more
1 Mar 2021 16:41

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

Read more
1 Mar 2021 15:36

Sensyne Health gets UK approval for 'SYNE-COV' algorithm

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health announced on Monday that its 'SYNE-COV' machine learning algorithm for Covid-19 risk prediction has achieved regulatory approval for use in the UK.

Read more
1 Mar 2021 15:34

TRADING UPDATES: 1Spatial expects full-year results ahead of forecasts

TRADING UPDATES: 1Spatial expects full-year results ahead of forecasts

Read more
9 Feb 2021 14:43

Sensyne Health signs licence agreement with Excalibur

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health has signed an exclusive licence and development agreement with Excalibur Healthcare Services, it announced on Tuesday, to apply Sensyne's 'MagnifEye' system for use with Excalibur's proprietary lateral flow rapid diagnostic tests across a range of indications, including its Covid-19 antigen test currently being marketed in the UK and Europe.

Read more
9 Feb 2021 11:18

TRADING UPDATES: Northbridge, discoverIE And Tandem Outlook Upbeat

TRADING UPDATES: Northbridge, discoverIE And Tandem Outlook Upbeat

Read more
5 Feb 2021 12:28

EXECUTIVE CHANGES: Iconic Labs CEO; Tiziana Hires Executive Director

EXECUTIVE CHANGES: Iconic Labs CEO; Tiziana Hires Executive Director

Read more
3 Feb 2021 11:07

IN BRIEF: Sensyne Health Launches AI Algorithm For Patient Management

IN BRIEF: Sensyne Health Launches AI Algorithm For Patient Management

Read more
21 Jan 2021 11:32

Sensyne Health Interim Loss Widens But Boasts Of Commercial Progress

Sensyne Health Interim Loss Widens But Boasts Of Commercial Progress

Read more
20 Jan 2021 19:18

IN BRIEF: Sensyne Health Signs Long-Term Deal With NHS Trust

IN BRIEF: Sensyne Health Signs Long-Term Deal With NHS Trust

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.